Dr. Tang Weikun, aged 36, joined Grand Pharma (China) Co., Ltd. (a major subsidiary of the Group) (“Grand Pharma (China)”) in 2012 and worked for several companies of the Group. He has been the assistant of the president of Grand Pharma (China) since April 2019, and was appointed as the president of Grand Pharma (China) with effect from 1 June 2021. Dr. Tang has overall responsible for the operation of Grand Pharma (China). Dr. Tang completed his life science and technology undergraduate education at Wuhan University in 2007, and obtained his doctoral degree in microbiology from the College of Life Sciences, Wuhan University in 2012.
Dr. Shao Yan
Chief Executive Officer
was appointed executive director of the Company in October 2008. Dr. Shao joined the Company in March 2008 and is the Chief Executive Officer of the Company. Dr. Shao is responsible for overseeing the entire operations and general management of the Company. He has over 20 years of experience in corporate management and venture capital investment. He hold a master’s degree in Business Administration from Guanghua School of Management of Peking University and a doctor degree (PhD) in Management from School of Politics and international Studies of Beijing Normal University.
Dr. Niu Zhanqi
Dr. Niu Zhanqi, aged 49, holds a bachelor degree of science from Nankai University and a doctorate (PhD) degree in pharmacy from Shenyang Pharmaceutical University. Dr. Niu has over ten years of medical research and development experience. He currently serves as Executive President of the Pharmaceutical Management Head Office of China Grand Enterprises Incorporation. He is also Director of Huadong Medicine Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 000963) since June 2016.
Dr. Shi Lin
Dr. Shi Lin, born in 1964, joined the Group in 2019 and is currently the deputy president and chief pharmaceutical officer of Grand Pharma (China). Before joining the Group, she had been the EU Registration Leader in Global Regulatory Affairs (GRA) Neuroscience of Janssen R&D in Belgium. Dr. Shi has over 30 years of clinical and research experience in the pharmaceutical industry, with significant experience working with global multifunctional matrix teams to drive forward complex projects. She led various applications for new drug clinical trials (Clinical Trial Applications (CTA) and Investigational New Drug Applications (IND)) in different countries in Europe and the United States, particularly in relation to strategic assessments in first clinical trials and innovative research paths. Dr. Shi obtained her doctoral degree in medical sciences from Vrije Universiteit Brussel in 2005. She has been appointed as professor and visiting fellow in various universities, such as Tongji Medical College affiliated to Huazhong University of Science and Technology. Dr. Shi was awarded as “2014 Top Ten Chinese Technology Leaders in Europe” (2014 度歐洲華人 10 大科技領軍人才*) by the Federation of Chinese Professional Association in Europe (全歐華人專業協會聯合會*).
was appointed independent non-executive director of the Company in March 2005. Ms So is a fellow member of the Association of Chartered Certified Accountants and a practicing member of the Hong Kong Institute of Certified Public Accountants. She is a partner of an accounting firm.
Dr. Pei Geng
Independent Non-Executive Director
Dr. Pei Geng is currently working in Multiway Trading Intl., USA and its Beijing branch, with TDR company in the USA. Dr. Pei has specialized in the areas of neurosurgery and neuroscience for over 20 years. Dr. Pei holds a bachelor degree in Medicine and became a clinician after graduation from Capital Medical University, Beijing, China. Dr. Pei also holds a licentiate degree in Medical Sciences from Uppsala University of Medicine, Sweden and a PhD degree in neuroscience from University of Würzburg, Germany.
Mr. Hu Yebi
Independent Non-Executive Director
Mr. Hu Yebi, received his Master of Business Administration from Netherlands International Institute for Management in the Netherlands and a Postgraduate Diploma in Management Engineering from Beijing Institute of Technology in Beijing, the PRC. Mr. Hu has more than twenty years of experience in securities and financial services, mergers and acquisitions and corporate finance. Mr. Hu is the founder and chairman of Vision Finance Group Limited. Mr. Hu is currently a non-executive director of Beijing Sports and Entertainment Industry Group Limited (stock code: 1803) and was an executive director of Tai United Holdings Limited (stock code: 718), Hua Lien International (Holding) Company Limited (stock code: 969), Beijing Enterprises Medical and Health Industry Limited (stock code: 2389) and Beijing Properties (Holdings) Limited (stock code: 925), but already resigned in October 2016, July 2017, October 2018 and November 2018 respectively. All these companies are listed on The Stock Exchange of Hong Kong Limited.